|
Synonyms: AG-014699 | AG014699 | AG14447 | PF-01367338 | Rubraca®
rucaparib is an approved drug (FDA (2016), EMA (2018))
Compound class:
Synthetic organic
Comment: Rucaparib is an orally active poly(ADP-ribose)polymerase (PARP) inhibitor with anti-cancer activity [7]. It was developed by Clovis Oncology.
PARP inhibitors are known to enhance efficacy of anti-cancer therapies such as DNA alkylating agents, topoisomerase I poisons, and ionizing radiation. Note that in the Thomas et al. paper [7], AG014699 refers to the phosphate salt and AG14447 to the parent molecule. Rucaparib was accepted for FDA priority review for the treatment of advanced ovarian cancer harbouring mutant BRCA (August 2016). Note: olaparib was the first PARP inhibitor to be approved for clinical use. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use  |
| In December 2016, the US FDA granted accelerated approval to rucaparib for treatment of patients with deleterious germline and/or somatic BRCA mutation associated advanced ovarian cancer who have been treated with two or more chemotherapies. Link here to a list of clinical trials assessing rucaparib registered with ClinicalTrials.gov. Phase 2 trial results are published in [6]. In April 2017, the FDA expanded approval to include use of rucaparib as maintenance treatment for recurrent ovarian, fallopian tube, or primary peritoneal cancer for patients who are in a complete or partial response to platinum-based chemotherapy. This desision was based on results from clinical trial NCT01968213 which were published in October 2017 [3]. Approval was further expanded by the FDA in April 2018, to include use as a maintenance treatment for epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer that is in complete or partial response to platinum-based chemotherapy (based on results from the ARIEL3 study NCT01968213). The EMA granted approval in May 2018, for the treatment of high-grade, BRCA mutation +ve cancers of the ovary, fallopian tubes and peritoneum that has been responsive to previous platinum-based chemotherapy [5]. In May 2020, the FDA authorised use of rucaparib (through its accelerated approval program) for the treatment of BRCA mutation +ve metastatic castration-resistant prostate cancer (mCRPC; previously treated with androgen receptor-directed therapy and a taxane-based chemotherapy). This approval was based on evidence from the TRITON2 clinical trial NCT02952534, which also evaluated rucaparib's potential in patients with genetic alterations in DNA damage repair genes other than BRCA [1]. |
| Mechanism Of Action and Pharmacodynamic Effects |
| PARP-1 (poly(ADP-ribose) polymerase 1) inhibitors enhance the efficacy of drugs/therapies which cause DNA damage (eg alkylating agents such as temozolomide , topoisomerase poisons such as topotecan and irinotecan and ionizing radiation) [2,4]. This action helps to promote cancer cell death, by preventing the DNA repair which is required for cell survival. Cells with mutations in other DNA repair enzymes such as BRCA become more dependent on PARP for DNA repair. In such malignant cells, inhibition of PARP may therefore result in cell death due to accumulated therapy-induced DNA damage. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01968213 | A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer | Phase 3 Interventional | Clovis Oncology, Inc. | ||
| External links |
|
For extended ADME data see the following: Drugs.com European Medicines Agency (EMA) |
